Skip to main content
ARIX BIOSCIENCE PLC logo

ARIX BIOSCIENCE PLC — Investor Relations & Filings

Ticker · ARIX ISIN · GB00BD045071 LEI · 213800OVT3AHQCXNIX43 IL Financial and insurance activities
Open in API
Filings indexed 547 across all filing types
Latest filing 2020-12-03 Regulatory Filings
Country GB United Kingdom
Listing IL ARIX

About ARIX BIOSCIENCE PLC

https://www.arixbioscience.com/

Arix Bioscience plc is a global venture capital company that specializes in the biotechnology and life sciences sectors. The firm's primary activity involves investing in and building innovative biotech companies, providing capital and strategic support from early stages, including seed, preclinical, and clinical development. Arix focuses on identifying and nurturing breakthrough advances in life sciences to accelerate the development of new medical technologies and therapies. According to public information, the company has entered into a process of liquidation.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 1% confidence The document is very short (1920 characters) and contains the header 'RNS Number : 4237H'. It announces a 'Price Monitoring Extension' related to trading on the London Stock Exchange and explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This structure—a brief announcement disseminated via the RNS system, often concerning market mechanics rather than comprehensive financial results or statutory reports—fits best under the general Regulatory Filings category (RNS), as it is a specific market notice that doesn't align with the definitions for 10-K, ER, IR, or DIV, etc. It is a regulatory/market communication.
2020-12-03 English
Artios and Merck KGaA announce global strategic collaboration
Regulatory Filings Classification · 1% confidence The document is a regulatory announcement disseminated via EQS Group, dated 03-Dec-2020, detailing a strategic collaboration between Arix Bioscience's portfolio company, Artios, and Merck KGaA. It discusses financial terms (upfront payments, milestones, royalties) related to drug discovery and development. This type of announcement, which details a significant business event (a major collaboration/deal) but is not a full financial report (like 10-K or IR), nor a management change (MANG), nor a capital raise (CAP), fits best under the general category for regulatory announcements that don't fit elsewhere, which is Regulatory Filings (RNS). It is not an Earnings Release (ER) or an Interim Report (IR) as it focuses on a specific corporate transaction rather than period performance.
2020-12-03 English
Arix to Present at the Jefferies Virtual London Healthcare Conference
Regulatory Filings Classification · 1% confidence The document is a short announcement (2985 characters) disseminated via EQS Group. The content explicitly states that the company 'Arix to Present at the Jefferies Virtual London Healthcare Conference' and provides details about the event (date, time, speaker, and webcast link). This structure—announcing participation in an external event rather than releasing core financial results, regulatory filings, or internal changes—is characteristic of a general corporate update. Since it is not a specific report (like 10-K, ER, or IR) but rather a notification about an upcoming event, and it doesn't fit other specific categories like DIRS, DIV, or MANG, it falls best under the general 'Regulatory Filings' category (RNS) as a miscellaneous regulatory announcement, or potentially a very broad interpretation of an Investor Presentation (IP) if the presentation itself was the focus, but here the focus is the *announcement* of the presentation. Given the 'MENU VS MEAL' rule, and the nature of this being a brief notification about an event, RNS is the most appropriate fallback for a non-specific corporate event announcement.
2020-11-12 English
Second Price Monitoring Extn
Capital/Financing Update Classification · 1% confidence The document is very short (1937 chars) and contains the header 'RNS Number : 4237E'. It describes a 'Second Price Monitoring Extension' related to trading activity on the London Stock Exchange. The text explicitly states, 'This information is provided by RNS, the news service of the London Stock Exchange.' This indicates it is a general regulatory announcement disseminated via the RNS system, rather than a specific financial report (like 10-K, IR, or ER). Since it is a general regulatory announcement that doesn't fit the other specific categories (like DIRS, DIV, or DLST), the most appropriate classification is the general Regulatory Filings fallback category.
2020-11-05 English
Price Monitoring Extension
Capital/Financing Update Classification · 1% confidence The document begins with 'RNS Number : 4230E' and is distributed by 'RNS, the news service of the London Stock Exchange.' It announces a 'Price Monitoring Extension' for a security, which is a specific, short regulatory announcement related to trading procedures. Given its nature as a general regulatory announcement disseminated via the RNS system and its brevity (under 5,000 characters), it fits best under the general Regulatory Filings category, as it does not correspond to any of the more specific financial report types (like 10-K, ER, or IR).
2020-11-05 English
Arix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion
Regulatory Filings Classification · 1% confidence The document is a formal announcement disseminated via EQS Group, titled 'Arix Bioscience PLC: VelosBio to be acquired by Merck for $2.75 billion'. It details a significant corporate transaction (acquisition of a portfolio company) and its financial implications for Arix Bioscience, including expected net proceeds and impact on Net Asset Value (NAV). This type of announcement, which concerns a major corporate event like a merger or takeover bid, aligns best with the M&A Activity category (TAR). While it is a regulatory announcement, TAR is more specific than the general 'RNS' fallback. It is not a full 10-K, an earnings release (ER), or a proxy statement (DEF 14A/PSI).
2020-11-05 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.